Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
NCT01452152 · University of Maryland, Baltimore · PHASE4 · terminated · last registry update 2022-03-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated by study sponsor.” | – | Registry record, University of Maryland, Baltimore |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against P2RY12 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-02-23Also stopped (terminated): Insel Gruppe AG, University Hospital Bern, a drug against P2RY12 (NCT02678871)
- 2023-02-08Phase 3 first posted: Assiut University, Rivaroxaban 2.5 Mg Oral Tablet twice daily + Clopidogrel 75 Mg Oral Tablet (NCT05718531)
- 2023-02-01Phase 3 first posted: Beijing Tiantan Hospital, Acetazolamide-based medical therapy (NCT05707442)
- 2023-01-30Phase 3 first posted: Rajaie Cardiovascular Medical and Research Center, Rivaroxaban 15 MG + Warfarin (NCT05705089)
- 2023-01-26Phase 3 first posted: The First Affiliated Hospital with Nanjing Medical University, Rivaroxaban + Clopidogrel (NCT05700266)
- 2023-01-18Also stopped (terminated): Imperial College London, Aspirin 75mg + Clopidogrel 75mg (NCT04333407)
- 2022-12-29Results posted on the registry: University of Arkansas, Ticagrelor 90mg + Clopidogrel 75mg (NCT03649711)
- 2022-12-20Phase 3 first posted: St. Antonius Hospital, Clopidogrel (NCT05657041)
- 2022-11-30Results posted on the registry: University of Nebraska, Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks (NCT01765400)
- 2022-11-25Phase 3 first posted: Centre Hospitalier Universitaire de Saint Etienne, Full-dose anticoagulant therapy (AC) + Antiplatelet therapy (AP) (NCT05627375)
- 2022-11-10Phase 3 first posted: Mercy Health Ohio, a drug against P2RY12 (NCT05611242)
- 2022-11-03Phase 3 first posted: Second Affiliated Hospital of Guangxi Medical University, Tirofiban Hydrochloride + Placebo (NCT05604638)
- 2022-10-13Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, a drug against P2RY12 (NCT05577988)
- 2022-10-04Phase 3 first posted: Jaime Daniel Mondragon, Dapagliflozin 10mg Tab + Statins (Cardiovascular Agents) (NCT05565976)
- 2022-09-26Phase 3 first posted: Azienda Ospedaliero Universitaria Maggiore della Carita, Aspirin 100mg + Aspirin 100 mg OD plus clopidogrel 75 mg OD (NCT05554822)
- 2022-09-23Phase 3 first posted: Kafrelsheikh University, Ticagrelor 90 MG Oral Tablet + Clopidogrel tablet (NCT05553613)
- 2022-08-19Phase 3 first posted: Beijing Tiantan Hospital, Recombinant Human Prourokinase for Injection (rhPro-UK) + standard medical treatment (NCT05507645)
- 2022-08-18Results posted on the registry: Inova Health Care Services, Vorapaxar + Vorapaxar and Aspirin (NCT03207451)
- 2022-07-20Results posted on the registry: University Hospitals Cleveland Medical Center, Clopidogrel + Ticagrelor (NCT02486367)
- 2022-06-27Results posted on the registry: University of Florida, Rivaroxaban 2.5 mg Tablet (NCT03718429)
- 2022-05-24Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Oral Anticoagulant, Direct-Acting + Antiplatelet therapy (NCT05387954)
- 2021-12-02Phase 3 first posted: Beijing Tiantan Hospital, tenecteplase (0.25 mg/kg, Max 25 mg) + standard medical treatment (NCT05141305)
- 2021-11-16Phase 3 first posted: University of Sao Paulo, ASA + Clopidogrel (NCT05122455)
- 2021-10-28Phase 3 first posted: University Hospital, Bordeaux, clopidogrel treatment + Placebo (NCT05098704)
- 2021-10-14Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Rivaroxaban 2.5 MG [Xarelto] + DAPT strategy (NCT05077683)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision